Exciting Participation in Upcoming Events
Soleno Therapeutics, Inc. (NASDAQ: SLNO), a pioneering biopharmaceutical company committed to the treatment of rare diseases, is set to make a significant mark in the investment community by participating in several prestigious investor conferences this September. These events foster crucial discussions on advancements in therapeutics and present an opportunity for Soleno to showcase its innovative solutions.
Cantor Global Healthcare Conference
Presentation Details
First on the agenda is the Cantor Global Healthcare Conference, where Soleno will be featured in a fireside chat format. This engaging conversation is scheduled for a later afternoon session, allowing investors to gain insight into the company’s strategies and upcoming projects.
Wells Fargo Healthcare Conference
Key Presentation Insights
The following day, Soleno will participate in the Wells Fargo Healthcare Conference, another notable platform for discussing investment opportunities in healthcare. This presentation promises to provide in-depth analysis and perspectives on the company’s trajectory and product developments.
H.C. Wainwright 27th Annual Global Investment Conference
Innovative Product Discussions
On September 8, Soleno will take part in the H.C. Wainwright 27th Annual Global Investment Conference. This event serves as a crucial opportunity for the company to present its flagship product, VYKAT™ XR, which targets hyperphagia in Prader-Willi syndrome. Investors will be keen to learn more about its market potential and future plans.
Baird Global Healthcare Conference and Bernstein Forum
Looking Ahead
The following week, Soleno will continue its robust presentation schedule with the Baird Global Healthcare Conference, followed by participation in the Bernstein 2nd Annual Healthcare Forum. Each of these events enables the company to communicate its vision and progress directly to potential investors and stakeholders.
In addition to live presentations, replays will be accessible in the Investors section of Soleno’s official website, ensuring that detailed information remains available for those who could not attend in real-time.
About Soleno Therapeutics, Inc.
Soleno Therapeutics stands at the forefront of developing novel therapies to address the needs of patients suffering from rare diseases. The company’s flagship offering, VYKAT™ XR (diazoxide choline) extended-release tablets, represents a significant advancement in treating hyperphagia associated with Prader-Willi syndrome. This oral treatment is available for both adults and children aged four and older, filling a critical gap in care for this population.
Corporate Contact Information
For further inquiries or detailed information regarding Soleno and its projects, please reach out to Brian Ritchie of LifeSci Advisors, LLC at 212-915-2578.
Frequently Asked Questions
What does Soleno Therapeutics specialize in?
Soleno Therapeutics is focused on the development and commercialization of innovative therapeutics aimed at treating rare diseases.
When will Soleno present at the Cantor Global Healthcare Conference?
Soleno will present at the Cantor Global Healthcare Conference on September 3 at 1:00 PM ET.
How can I access the replays of the conferences?
The replays of the Cantor and Wells Fargo presentations will be available on Soleno's official website in the Investors section.
What is VYKAT™ XR?
VYKAT™ XR is Soleno's first commercial product, designed to treat hyperphagia in individuals diagnosed with Prader-Willi syndrome.
Who can be contacted for inquiries about Soleno?
Inquiries can be directed to Brian Ritchie at LifeSci Advisors, LLC, via phone at 212-915-2578.